Sub-group analyses: studies including patients with comorbidities versus studies excluding patients with comorbidities
| Quality assessment | Number of events | Relative effect | Absolute effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies * | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ADT | No ADT | RR | 95% CI | ||
| Cardiovascular mortality in patients with no comorbidities (median follow-up 3.8 years) | ||||||||||||
| 1 | Cohort | None | None | Serious | Serious1 | None | 51 / 1015 (5.0%) | 80 / 3877 (2.1%) | 2.44 | 1.73 – 3.44 | 28 more per 1,000 (from 15 more to 47 more) | VERY LOW |
| Cardiovascular mortality in patients with comorbidities (median follow-up 3.8 years) | ||||||||||||
| 6 | 2 cohorts & 4 RCTs | None | Serious2 | Serious | Serious1 | None | 402 / 7627 (5.3%) | 374 / 11240 (3.3%) | 1.24 | 0.78 – 1.95 | 8 more per 1,000 (from 7 fewer to 30 more) | VERY LOW |
| Cerebrovascular accident morbidity in patients with no comorbidities (median follow-up not reported) | ||||||||||||
| 1 | Cohort | Serious3 | None | Serious | Serious1 | None | 11 / 64 (17.2%) | 57 / 301 (18.9%) | 0.91 | 0.50 – 1.63 | 14 fewer per 1,000 (from 85 fewer to 86 more) | VERY LOW |
| Cerebrovascular accident morbidity in patients with comorbidities (median follow-up 4.0 – 6.5 years) | ||||||||||||
| 3 | Cohorts | Serious3 | None | None | None | None | 4339 / 60985 (7.1%) | 5131 / 81556 (6.3%) | 1.10 | 0.86 – 1.41 | 6 more per 1,000 (from 9 fewer to 26 more) | VERY LOW |
Wide confidence intervals reported.
Some studies report lower risk in ADT patients while other report a higher risk.
Inadequately short follow-up where reported.
From: 7, Hormone therapy
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.